SCHEMBL3934544

SCHEMBL3934544

NC(=O)CC1(c2ccccc2)CCN(Cc2ccccc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPFFR1 Q9GZQ6 1/20 0.60
NPFFR2 Q9Y5X5 1/20 0.60
OPRL1 P41146 1/20 0.57
POLB P06746 1/20 0.56
TSHR P16473 2/20 0.54
CYP2D6 P10635 4/20 0.52
ALDH1A1 P00352 3/20 0.52
MAPK1 P28482 2/20 0.50
OPRM1 P35372 2/20 0.50
CHRM2 P08172 1/20 0.50
CHRM3 P20309 1/20 0.50
MEN1 O00255 1/20 0.50
LMNA P02545 1/20 0.50
MAPT P10636 1/20 0.50
KMT2A Q03164 1/20 0.50
CCR3 P51677 1/20 0.49
CYP3A4 P08684 3/20 0.49
HSD17B10 Q99714 1/20 0.49
CACNA1G O43497 1/20 0.47
SIGMAR1 Q99720 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2957008 0.84 TSHR (0.58) OPRL1POLBTSHRCYP2D6ALDH1A1
SCHEMBL28611554 0.83 NPFFR1 (0.58) NPFFR1NPFFR2OPRL1POLBTSHR
SCHEMBL28761346 0.81 CYP2D6 (0.56) OPRL1POLBTSHRCYP2D6ALDH1A1
SCHEMBL16565921 0.81 P2RX7 (0.53) ALDH1A1OPRM1CHRM3MAPTKMT2A
SCHEMBL21077873 0.81 MAOA (0.41) NPFFR1NPFFR2TSHROPRM1MEN1
SCHEMBL2789160 0.80 OPRL1 (0.66) NPFFR1NPFFR2OPRL1POLBTSHR
SCHEMBL2470240 0.80 MAOA (0.61) NPFFR1NPFFR2OPRL1POLBTSHR
SCHEMBL6628915 0.80 CHRM2 (0.43) NPFFR1NPFFR2OPRL1TSHRMAPK1
SCHEMBL476242 0.79 OPRL1 (0.60) NPFFR1NPFFR2OPRL1POLBTSHR
SCHEMBL2842737 0.79 NPFFR1 (0.69) NPFFR1NPFFR2OPRL1POLBCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3310774-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 Novartis AG (CH) 2018-04-25 EP disclosed
WO-2016203406-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 NOVARTIS AG (CH) 2016-12-22 WO disclosed
US-7572913-B2 Inhibitors of Rho kinase; N-Benzyloxycarbonyl-4-[N''-(tert-butyloxycarbonyl)hydrazino]piperidine; 4-{[N''-(tert-butyloxycarbonyl)-N'-(1'-propyl)]hydrazino}piperidine BIOAXONE THERAPEUTIQUE INC. (CA) 2009-08-11 US disclosed
EP-1720874-A1 4-SUBSTITUTED PIPERIDINE DERIVATIVES Bioaxone Therapeutique Inc. (CA) 2006-11-15 EP disclosed
US-20050272751-A1 4-Substituted piperidine derivatives BIOAXONE THERAPEUTIQUE INC. (CA) 2005-12-08 US disclosed
WO-2005080394-A1 4-SUBSTITUTED PIPERIDINE DERIVATIVES BIOAXONE THERAPEUTIQUE INC. (CA) 2005-09-01 WO disclosed
US-20040077667-A1 Quinazolinone derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272751-A1 4-Substituted piperidine derivatives RHOC, PRPH, RHOT2 NPFFR1 785/4885NPFFR2 1368/4885OPRL1 688/4885
US-20040077667-A1 Quinazolinone derivatives PARP1, PARP9, PARP2 NPFFR1 3953/4885NPFFR2 4316/4885OPRL1 2600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.